SCHEMBL11943890

SCHEMBL11943890

O=c1c(OCCCC2CCCCC2)c(N2CCN(S(=O)(=O)c3cccs3)CC2)cnn1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.44
▸ TSHR P16473 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ DCTPP1 Q9H773 1/20 0.41
▸ PKM P14618 2/20 0.41
▸ THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945015 0.92 MAPT (0.47) MAPTTSHRGAASMN1; SMN2HTT
SCHEMBL11943889 0.87 MAPT (0.53) MAPTTSHRGAASMN1; SMN2HTT
SCHEMBL11943895 0.87 MAPT (0.48) MAPTTSHRGAASMN1; SMN2HTT
SCHEMBL11945009 0.86 MAPT (0.48) MAPTTSHRGAASMN1; SMN2HTT
SCHEMBL11943872 0.86 MAPT (0.52) MAPTTSHRGAASMN1; SMN2HTT
SCHEMBL11945008 0.86 MAPT (0.54) MAPTTSHRGAASMN1; SMN2HTT
SCHEMBL11944424 0.86 SMN1; SMN2 (0.48) MAPTTSHRGAASMN1; SMN2HTT
SCHEMBL11944990 0.85 MAPT (0.52) MAPTTSHRGAASMN1; SMN2HTT
SCHEMBL11943875 0.85 MAPT (0.52) MAPTTSHRGAASMN1; SMN2HTT
SCHEMBL11944991 0.85 MAPT (0.52) MAPTTSHRGAASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885TSHR 4729/4885GAA 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback